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ABSTRACT
Introduction: Hyperglycemia is a frequent
complication of parenteral nutrition (PN) in
patients both with and without diabetes mellitis
(DM). The aim of this study was to evaluate the
quality of glucose control achieved with basal
plus-correction insulin in surgical patients with
and without a history of DM receiving PN.
Methods: Retrospective evaluation of a proto-
col applied during the period of January
2013–December 2015. The insulin dose was
started at 0.4 and 0.3 IU/kg/day in patients with
previous DM and without a history of DM,
respectively, and the target blood glucose (BG)
was\ 180 mg/dl. Mean BG levels, insulin total
daily dose (TDD) and hypoglycemic (\ 70 mg/
dl) events on different days of PN were also
evaluated.
Results: Forty-one patients with previous type
2 DM and 39 without DM were evaluated. Gly-
cemic control in both groups was as follows:
during the first 48 h (230.4 ± 67 vs.
189.4 ± 38 mg/dl, p = 0.002); at the midpoint
(224.6 ± 58 vs. 181.3 ± 27 mg/dl, p = 0.003);
48 h before ending TPN (196.4 ± 43 vs.
169.8 ± 40 mg/dl, p = 0.004). Insulin TDD was
0.5 ± 0.3 U/kg/day in patients with DM and
0.37 ± 0.3 units/kg/day in those without DM
(p\ 0.05). A total of 18 patients experienced
hypoglycemic events, without differences
between the groups.
Conclusion: A basal-correction insulin regimen
is an alternative method for managing hyper-
glycemia in non-critically ill surgical patients
on PN.
Keywords: Diabetic patients; Hyperglycemia;
Non-diabetic patients; Parenteral nutrition
INTRODUCTION
Hyperglycemia is an important side effect in
patients receiving parenteral nutrition [1]
because of its high prevalence and has been
associated with adverse outcomes [2].
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The prevalence of hyperglycemia in patients
receiving PN is high and reported in more than
40% of these patients [3–5]. Most studies refer to
critically ill patients because their hyperme-
tabolic state makes controlling glucose levels
difficult, and there are few studies of non-criti-
cally ill patients, who are expected to have a
better tolerance of the glucose load. PN-related
hyperglycemia is associated with poor clinical
outcomes in patients with and without DM as
well as those who are either critically or non-
critically ill [6–9]. In surgical patients, hyper-
glycemia increases risks of perioperative com-
plications, length of stay and mortality [10, 11].
Both the consensus statement by the Amer-
ican Diabetes Association (ADA) and the
American Association of Clinical Endocrinolo-
gists (AACE) as well the clinical practice guide-
line of the Endocrine Society recommend a pre-
meal BG level\140 mg/dl and random BG
values\ 180 mg/dl [12, 13]. Furthermore, the
American Society for Parenteral and Enteral
Nutrition recommends a blood glucose goal of
140–180 mg/dl for hospitalized patients receiv-
ing nutritional support [14].
Insulin is the treatment of choice to control
hyperglycemia during PN. Subcutaneous insulin
administration, intravenous insulin infusion and
additionof insulin to thePNbaghavebeenshown
to be effective in managing hyperglycemia in
these patients [5, 13, 15, 16]. However, there are
few data from clinical trials comparing different
strategies [17], particularly in non-critically ill
patients [18, 19]. Furthermore, insulin protocols
vary widely between institutions.
In our hospital, a program for hyperglycemia
management based on a published protocol was
established [20]. For non-critically ill patients
under continuous PN, a basal plus correction
insulin regimen was set up. The aim of this
study was to evaluate the quality of glucose
control achieved by this strategy in surgical
patients with and without a history of DM
receiving PN.
METHODS
A retrospective study of surgical patients
receiving PN during the period of January
2013–December 2015 was performed at the
Hospital de la Santa Creu i Sant Pau in Barce-
lona, Spain. Data were retrieved from the hos-
pital’s electronic medical records. Patients with
or without a previous history of DM treated
with a basal plus correction insulin regimen
were included. In the diabetic patient group,
those with no record of DM but a glycated
hemoglobin (HbA1c) measurement C 6.5% or
fasting plasma glucose C 126 mg/dl were also
included. Patients were excluded if they were
transfered to intensive care units (ICUs), the
duration of the PN was\5 days or[60 days, or
they had recieved pharmacologic doses of cor-
ticosteroids. The study was approved by the
Ethics Committee of our institution, the
Hospital de la Santa Creu i Sant Pau.
Parenteral Nutrition Administration
The TPN formula was provided as a total nutri-
ent admixture solution containing carbohy-
drates, proteins and lipids, with daily
adjustments according to the individual caloric
and nutritional requirements of the patients.
PN administration provides approximately
50–60% of the calculated daily carbohydrate
caloric requirements during the first 24 h and
was increased to the desired goal during the
next 24 h. The glucose range administered was
between 150 and 250 g.
Blood Glucose Monitoring and Insulin
Therapy Protocol
In all patients receiving PN, capillary BG was
monitored every 6 h and was discontinued in
patients without a prior history of DM if glucose
values were\140 mg/dl without insulin ther-
apy for 48 h with the desired caloric intake.
Insulin therapy was indicated for all patients
with previous DM under pharmacologic ther-
apy. In DM patients treated exclusively with a
diet and in those without a history of DM,
insulin therapy was indicated if blood glucose
levels were[ 180 mg/dl. Patients with previous
replacement insulin therapy with a basal-bolus
regimen or C two doses of intermediate-acting
or premixed insulin were started at their
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previous total daily dose (TDD), and in the
remaining patients the initial TDD was esti-
mated as 0.4 U/kg/day.
The TDD was administered as basal insulin
glargine once daily, and correction doses of
insulin lispro were administered every 6 h if
glycemia remained above 180 mg/dl. The glar-
gine insulin dose was increased or decreased by
10–20% every day to achieve a glycemic goal of
140–180 mg/dl.
The glycated hemoglobin (HbA1c) was
determined in all patients with previous dia-
betes and in non-diabetic patients who required
insulin therapy.
Outcome Measures
The primary outcome of this study was to
determine the quality of glycemic control as
measured by mean daily BG levels 48 h after
initiation of PN treatment, at the midpoint of
the treatment period and 48 h before ending
PN. The number of hypoglycemic (\70 mg/dl)
events and TDD of insulin were also deter-
mined, and information on the demographics,
DM characteristics, type of surgery, BG on
admission and hospital length of stay (LOS)
were collected.
Statistical Analysis
All statistical analyses were performed with the
STATA 13 statistical program.
A p value \ 0.05 was set as statistically
significant.
Descriptive statistics using frequencies to
summarize categorical variables (percentage)
and expressing quantitative variables as
mean ± standard deviation (SD) were per-
formed. Normal distribution of quantitative
data was assessed using the Shapiro-Wilk test.
The univariate tests used were chi-square for
categorical variables and Student’s t-test for
quantitative variables. Paired Student’s tests
were performed to search for statistical differ-
ences in the variables between DM and non-DM
patients.
Compliance with Ethics Guidelines
All procedures performed in studies involving
human participants were in accordance with
the ethical standards of the institutional and/or
national research committee and with the 1964
Helsinki Declaration and its later amendments
or comparable ethical standards. Informed
consent was obtained from all individual par-
ticipants included in the study.
RESULTS
The baseline characteristics of the 80 patients
who met the eligibility criteria are shown in
Table 1. There were no significant differences in
age, body mass index, weight, mean LOS, type
of surgery or mean duration of PN between DM
and non-DM patients. The most common rea-
son for indicating PN was a paralytic ileus.
Patients with a prior history of DM had signifi-
cantly higher admission BG and HbA1c values
(Table 2).
Glycemic Control
Mean daily BG concentrations during the hos-
pital stay are shown in Fig. 1.
In all patients the mean BG levels during the
first 48 h of PN, at the midpoint period of PN
and 48 h before ending PN were 209.9 ± 58,
201.1 ± 43 and 183.1 ± 44 mg/dl, respectively.
Patients with previous DM had higher mean BG
concentrations at the three study times (Fig. 1).
There were no differences between DM patients
with or without previous insulin therapy during
the first 48 h of PN (230.5 ± 67 vs.
221.6 ± 70 mg/dl), at the midpoint of the per-
iod with PN (221.8 ± 58 vs. 233.0 ± 60 mg/dl)
and 48 h before ending PN (196.4 ± 43 vs.
193.92 ± 43 mg/dl), p[ 0.05. The proportion
of patients who achieved BG \ 180 mg/dl is
shown in Fig. 2.
Eighteen (22.5%) patients experienced mild
hypoglycemic events and six (7.5%) severe
hypoglycemic events, with no differences
between patients with or without previous DM.
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Table 1 Clinical characteristics of the study patients (n = 80)
Variables All patients
(n = 80)
Diabetic patients
(n = 41)
Non-diabetic patients
(n = 39)
p value*
Age (years) 77.6 ± 9.1 77.6 ± 9.1 74.3 ± 10.4 0.07
Gender 0.27
Male, n (%) 50 (62.5) 28 (68.3) 22 (56.4)
Female, n (%) 30 (37.5) 13 (31.7) 17 (43.6)
BMI (kg/m2) 27.3 ± 4.8 26.8 ± 5.2 27.8 ± 4.4 0.16
Body weight (kg) 73.5 ± 14.2 74.8 ± 13.5 72.1 ± 14.9 0.19
HbA1c (%) 6.8 ± 1.1 7.1 ± 1.1 6.2 ± 0.9 0.003
Previous diabetes treatment
Diet, n (%) – 9 (22) – –
Oral agents, n (%) – 19 (46)
Basal insulin ? oral agents,
n (%)
– 4 (10) – –
Basal insulin, n (%) – 7 (17) – –
Basal–bolus insulin, n (%) – 2 (5) – –
Type of surgery 0.43
Non-neoplasia surgery, n (%) 24 (30) 14 (34.2) 10 (25.6)
Colorectal cancer, n (%) 19 (23.8) 11 (26.8) 8 (20.5)
Pancreatic cancer, n (%) 18 (22.5) 6 (14.6) 12 (30.8)
Other cancer 14 (17.5) 6 (14.6) 8 (20.5)
Vascular surgery, n (%) 2 (2.5) 2 (4.9) –
Gynecologic cancer, n (%) 3 (3.7) 2 (4.9) 1 (2.6)
TPN indication 0.09
Ileus 73 (91.3) 40 (97.6) 33 (84.6)
Fistula 3 (3.7) – 3 (7.7)
Wound breakdown 4 (5) 1 (2.4) 3 (7.7)
Duration of PN (days) 12 ± 8 13.2 ± 8.5 10.9 ± 7.6 0.89
Length of hospital stay (days) 30.7 ± 14.5 30.8 ± 14.3 30.7 ± 14.9 0.52
Data are mean ± standard deviation
*Difference between diabetic and non-diabetic patients
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Most hypoglycemic episodes were due to
unplanned discontinuation of PN.
Insulin Dose
Insulin requirements are shown in Table 2. The
TDD of insulin during PN was 30.2 ± 20 units
or 0.43 ± 0.3 U/kg/day. In patients with DM,
the TDD was 0.5 ± 0.3 U/kg/day
(35.1 ± 21 U/day) and, in those with no history
of DM, 0.37 ± 0.3 U/kg/day (25.3 ± 19 U/day),
p\0.05. The insulin glargine dose increased
while the correctional insulin lispro decreased
from the start until 48 h before ending the PN.
Newly Diabetic Patients
We identified five newly diabetic patients, and
the mean HbA1c was 7.2% ± 0.6%. At dis-
charge, three patients received basal insulin and
two oral agents.
DISCUSSION
This retrospective study aimed to evaluate the
quality of glucose control achieved by a basal
plus correction insulin regimen in surgical
patients with and without a history of DM
receiving PN. Our study confirms that
Table 2 Difference in glycemic control, hypoglycemic events and insulin treatment (n = 80)
Variables All patients
(n = 80)
Diabetic patients
(n = 41)
Non-diabetic patients
(n = 39)
p value*
Mean BG at admission (mg/dl) 165.9 ± 63 180.7 ± 66 146.3 ± 57 0.015
Total mean insulin dose, U/day 30.2 ± 20 35.1 ± 21 25.3 ± 19 0.02
Total mean insulin dose,
U/kg/day
0.43 ± 0.3 0.50 ± 0.3 0.37 ± 0.2 0.05
48 h after start of PN
Mean BG (mg/dl) 209.9 ± 58 230.5 ± 67 189.4 ± 38 0.002
Glargina insulin, U/day 11.5 ± 19 14.3 ± 20 8.5 ± 18 0.11
Lispro insulin, U/day 13.5 ± 20 16.9 ± 13 9.9 ± 8 0.007
Midpoint period of PN
Mean BG (mg/dl) 201.1 ± 43 221.8 ± 58 180.1 ± 17 0.003
Glargina insulin, U/day 21.0 ± 26 26.0 ± 31 15.6 ± 18 0.03
Lispro insulin, U/day 15.4 ± 9 16.7 ± 11 14.0 ± 7 0.12
48 h before ending PN
Mean BG (mg/dl) 183.1 ± 44 196.4 ± 43 169.8 ± 40 0.004
Glargina insulin, U/day 28.2 ± 28 28.2 ± 28 15.6 ± 18 0.02
Lispro insulin, U/day 13.3 ± 9 13.3 ± 9 7.8 ± 6 0.001
Hypoglycemic events
BG\ 70 mg/dl, n (%) 9 (22) 9 (22) 9 (23) 0.53
BG\ 40 mg/dl, n (%) 2 (5) 2 (5) 4 (10)
Data are mean ± standard deviation
BG blood glucose
*Difference between diabetic and non-diabetic patients
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subcutaneous insulin with basal and correction
components is an adequate method for achiev-
ing and maintaining glucose control in non-
critically ill hospitalized patients with PN and
extends our knowledge as it was performed
during regular clinical practice.
People with DM have a higher probability of
requiring surgery during their lifetime than
those without DM [21]. In addition, hyper-
glycemia is a frequent complication of PN in
patients both with and without DM. Develop-
ment of hyperglycemia during PN increases the
risk of complications and mortality [7, 22, 23],
and several studies have demonstrated that
hyperglycemia treatment reduces rates of
infections and mortality in surgical patients
with diabetes [10, 24, 25].
Studies that evaluate hyperglycemia treat-
ment in patients receiving PN are scarce and
include both critically ill and non-critically ill
patients. Glycemic targets are heterogeneous,
and intervention includes the incorporation of
insulin with PN solution [16] and administra-
tion of long-acting insulin [19]. Only one study
has compared these strategies in surgical
patients receiving PN [18], and the results con-
firm that both glargine insulin and regular
insulin in the PN are effective modalities for BG
control. Moreover, a recent meta-analysis con-
firms that the most fitting insulin regimen to
treat hyperglycemia in hospitalized patients on
nutritional support has not been established
[17]. Accordingly, there is a lack of standardized
protocols for monitoring and therapy in this
population, and strategies are those recom-
mended for hospitalized non-critically ill
patients [5, 12, 13, 20, 26].
Although there is no clear evidence for
specific BG goals in non-critically ill patients,
pre-meal BG targets\140 mg/dl with random
BG\180 mg/dl are considered reasonable
[12, 13, 20, 26]. Glucose management typically
involves subcutaneous insulin administered as a
basal/bolus/correction regimen with adequate
adjustments as the patient’s condition changes
[12, 13, 20]. In patients on PN, as the rate of
glucose infusion is expected to be flat and
remain in a postprandial state, a basal plus
correction insulin regimen and a BG target \
180 mg/dl were established.
The target BG\ 180 mg/dl was achieved in
only 50% of patients, equaling overall glycemic
control rates obtained in a recent study with
glargine insulin (52.24%) and regular insulin in
the PN bag (47.76%) [18]. As expected, a high
percentage of patients with a previous history of
DM did not reach the glycemic target. The
average TDD of insulin measured 0.5 U/kg/day
in patients with previous DM and 0.37 U/kg/day
in those with no history of DM, in accordance
with current recommendations for hospitalized
patients as initial insulin doses [13, 27, 28].
Therefore, an initial insulin dose estimated at
0.4 U/kg/day seems to be adequate for most
patients, and perhaps the main reason for not
Fig. 1 Glycemic control in all patients, diabetic and non-
diabetic patients in relation to the time of PN. *Difference
between diabetic and non-diabetic patients. *p\ 0.05
Fig. 2 Proportion of patients with BG\180 mg/dl in the
three study periods
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achieving reasonable glycemic control was the
lack of dose adjustment.
The prevalence of hypoglycemia in patients
receiving PN is not well known and has been
related to an increase in complications and
mortality [29]. The percentage ranges from a
low of around 4% up to 40% [30]. In our report,
22.5% of patients experienced BG
levels\ 70 mg/dl and 7.5%\ 40 mg/dl. Most
episodes were due to unplanned discontinua-
tion of PN and lack of communication with the
endocrinology team, a common occurrence in
hospital wards.
The limitations of the present study include
a retrospective design that led to exclusion of
subjects whose data were incomplete. As the
study was performed during regular clinical
practice, it provides information on the appli-
cability of a basal-correction insulin regimen in
this context. Since our study did not aim to
compare different strategies, conclusions
regarding the most appropriate method to
manage hyperglycemia could not be reached
based on this study. Larger studies are needed to
determine the optimal glycemic control strate-
gies in patients with PN.
CONCLUSIONS
The results of our study show that in regular
clinical practice subcutaneous insulin with
basal and correction components is an adequate
method for management of hyperglycemia in
non-critically ill hospitalized surgical patients
with PN.
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